Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by MedImmune LLC
Sponsor:
Information provided by (Responsible Party):
MedImmune LLC
ClinicalTrials.gov Identifier:
NCT01843374
First received: April 22, 2013
Last updated: September 19, 2014
Last verified: September 2014
  Purpose

This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo. Approximately 564 subjects will be enrolled at study centers in multiple countries. The study consists of a screening period, a treatment period, a 90-day follow-up period for safety, and a long-term survival follow-up period.


Condition Intervention Phase
Unresectable Pleural or Peritoneal Malignant Mesothelioma
Drug: Tremelimumab
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma

Resource links provided by NLM:


Further study details as provided by MedImmune LLC:

Primary Outcome Measures:
  • Overall survival (OS) time by treatment arm [ Time Frame: Time from randomization until death due to any cause, assessed up to 3 years. ] [ Designated as safety issue: No ]
    The primary analysis of OS is defined as the time from randomization until death due to any cause.


Secondary Outcome Measures:
  • Durable disease control rate by treatment arm [ Time Frame: Time from randomization to disease progression or death, whichever occurs first, assessed up to 3 years. ] [ Designated as safety issue: No ]
    Durable DCR is defined as the proportion of participants with best response of complete response (CR), partial response (PR), or stable disease (SD) of ≥ 6 months duration

  • Length of progression-free survival by treatment arm [ Time Frame: Time from randomization to disease progression or death, whichever occurs first, assessed up to 3 years. ] [ Designated as safety issue: No ]
    Progression-free survival will be measured from randomization to the first documentation of disease progression or death due to any cause, whichever occurs first.

  • Overall response rate by treatment arm [ Time Frame: Time from randomization to disease progression or death, whichever occurs first, assessed up to 3 years. ] [ Designated as safety issue: No ]
    Overall response rate is defined as the proportion of participants with confirmed CR or PR.

  • Duration of response by treatment arm [ Time Frame: Time from randomization to disease progression or death, whichever occurs first, assessed up to 3 years. ] [ Designated as safety issue: No ]
    Duration of response will be defined as the duration from the first documentation of objective response (CR or PR) to the first documented disease progression.

  • Number of participants reporting any adverse event [ Time Frame: Day 1- 90 days post dose ] [ Designated as safety issue: Yes ]
    Any untoward medical occurrence in a patient or clinical investigation participants administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

  • Number of participants with changes in patient-reported outcomes [ Time Frame: Time from randomization to disease progression or death, whichever occurs first, assessed up to 3 years. ] [ Designated as safety issue: No ]
    Patient-reported outcomes as measured by the LCSS-Meso (for disease-related symptoms and health-related QoL), EQ-5D-3L (for health status), and BPI-sf (for pain) will be summarized descriptively; the change from baseline for total score and individual domain scores by treatment arm at each time point will be explored.

  • Number of participants reporting any serious adverse events [ Time Frame: Day 1 to 90 days post dose ] [ Designated as safety issue: Yes ]
  • Number of participants with anti-drug antibodies [ Time Frame: Week 5 ] [ Designated as safety issue: No ]
    The immunogenicity titer will be reported for samples confirmed positive for the presence of anti tremelimumab antibodies.

  • Tremelimumab blood concentration [ Time Frame: Week 5 ] [ Designated as safety issue: No ]
    Tremelimumab concentration data and summary statistics will be tabulated.

  • OS rate at 18 months [ Time Frame: Time from randomization until death, due to any cause, or alive at 18 months. ] [ Designated as safety issue: No ]

Estimated Enrollment: 564
Study Start Date: May 2013
Estimated Study Completion Date: April 2016
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tremelimumab
Tremelimumab
Drug: Tremelimumab
Tremelimumab is to be administered as an IV solution, followed by observation.
Placebo Comparator: Placebo
Placebo
Drug: Placebo
Placebo is to be administered as an IV solution, followed by observation.

Detailed Description:

This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo.

Randomization will be stratified by EORTC status (low-risk vs high-risk), line of therapy (second vs third), and anatomical site (pleural vs peritoneal). This study plans to use the EORTC to stratify subjects into high or low risk groups in order to ensure balanced randomization to the different treatment groups. For subjects in whom pemetrexed was contraindicated or not tolerated or not an approved therapy (eg, peritoneal mesothelioma), prior therapy with a first-line platinum-based regimen is required. Approximately 564 subjects will be enrolled at study centers in multiple countries.

The study consists of a screening period, a treatment period, and a 90-day follow-up period.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically and/or cytologically confirmed pleural or peritoneal malignant mesothelioma. Disease not amenable to curative surgery;
  • Age 18 and over at the time of consent;
  • ECOG Performance status 0-1;
  • Progressed after previous receipt of 1-2 prior systemic treatment for advanced disease that included a first-line pemetrexed (or anti-folate)-based regimen in combination with platinum agent;
  • Recovered from all toxicities associated with prior treatment; - Measurable disease; - Adequate bone marrow, hepatic, and renal function

Exclusion Criteria:

  • Received any prior monoclonal antibody against CTLA-4, programmed cell death 1 (PD1) or programmed cell death 1 ligand 1 (PD-L1);
  • History of chronic inflammatory or autoimmune disease;
  • Active, untreated central nervous system (CNS) metastasis;
  • History of other malignancy unless the subject has been disease-free for at least 3 years;
  • Active or history of diverticulitis. Note that diverticulosis is permitted;
  • Active or history of inflammatory bowel disease (eg, colitis, Crohn's), irritable bowel disease, celiac disease or other serious gastrointestinal chronic conditions associated with diarrhea. Active or history of systemic lupus erythematosis or Wegener's granulomatosis;
  • History of sarcoidosis syndrome;
  • Currently receiving systemic corticosteroids or other immunosuppressive medications;
  • The last dose of prior chemotherapy or radiation therapy (with the exception of palliative radiotherapy) was received less than 2 weeks prior to randomization;
  • Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy; with the exception of vitiligo and alopecia.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01843374

Contacts
Contact: MedImmune Contact ClinicalTrialEnquiries@Medimmune.com

  Hide Study Locations
Locations
United States, Arizona
Research Site Recruiting
Scottsdale, Arizona, United States
United States, California
Research Site Recruiting
La Jolla, California, United States
Research Site Recruiting
Los Angeles, California, United States
Research Site Recruiting
San Francisco, California, United States
Research Site Recruiting
Santa Monica, California, United States
United States, Connecticut
Research Site Recruiting
New Haven, Connecticut, United States
United States, Delaware
Research Site Recruiting
Newark, Delaware, United States
United States, Florida
Research Site Not yet recruiting
Orlando, Florida, United States
Research Site Recruiting
Tampa, Florida, United States
United States, Georgia
Research Site Recruiting
Augusta, Georgia, United States
United States, Illinois
Research Site Recruiting
Chicago, Illinois, United States
Research Site Recruiting
Peoria, Illinois, United States
United States, Maryland
Research Site Recruiting
Baltimore, Maryland, United States
United States, Michigan
Research Site Withdrawn
Detroit, Michigan, United States
United States, Minnesota
Research Site Recruiting
Minneapolis, Minnesota, United States
United States, New York
Research Site Not yet recruiting
New York, New York, United States
Research Site Recruiting
New York, New York, United States
Research Site Recruiting
Rochester, New York, United States
United States, North Carolina
Research Site Recruiting
Durham, North Carolina, United States
United States, Ohio
Research Site Recruiting
Canton, Ohio, United States
Research Site Recruiting
Cleveland, Ohio, United States
United States, Oregon
Research Site Recruiting
Portland, Oregon, United States
United States, Pennsylvania
Research Site Recruiting
Philadephia, Pennsylvania, United States
United States, Texas
Research Site Recruiting
Dallas, Texas, United States
Research Site Recruiting
Houston, Texas, United States
Australia
Research Site Recruiting
Adelaide, Australia
Research Site Recruiting
Auchenflower, Australia
Research Site Recruiting
Box Hill, Australia
Research Site Recruiting
Chermside, Australia
Research Site Recruiting
East Bentleigh, Australia
Research Site Recruiting
Garran, Australia
Research Site Recruiting
Gosford, Australia
Research Site Not yet recruiting
Hamlyn Terrace, Australia
Research Site Recruiting
Heidelberg, Australia
Research Site Recruiting
Nedlands, Australia
Research Site Not yet recruiting
Richmond, Australia
Research Site Recruiting
Saint Leonards, Australia
Research Site Recruiting
Southport, Australia
Research Site Recruiting
Waratah, Australia
Research Site Not yet recruiting
Wollongong, Australia
Belgium
Research Site Recruiting
Antwerp, Belgium
Research Site Not yet recruiting
Brussels, Belgium
Research Site Recruiting
Gent, Belgium
Research Site Recruiting
Leuven, Belgium
Research Site Not yet recruiting
Mons, Belgium
Brazil
Research Site Not yet recruiting
Porto Alegre, Brazil
Research Site Not yet recruiting
Rio de Janeiro, Brazil
Research Site Not yet recruiting
Sao Paulo, Brazil
Canada, Ontario
Research Site Recruiting
Toronto, Ontario, Canada
Canada, Quebec
Research Site Recruiting
Montreal, Quebec, Canada
Research Site Not yet recruiting
Montreal, Quebec, Canada
Research Site Recruiting
Sainte Foy, Quebec, Canada
Denmark
Research Site Recruiting
Copenhagen, Denmark
France
Research Site Recruiting
Caen Cedex, France
Research Site Not yet recruiting
Caen cedex, France
Research Site Not yet recruiting
Chauny, France
Research Site Recruiting
Clamart Cedex, France
Research Site Not yet recruiting
La Tronche, France
Research Site Recruiting
Le Mans Cedex, France
Research Site Recruiting
Lille Cedex, France
Research Site Not yet recruiting
Marseille Cedex 20, France
Research Site Recruiting
Nice Cedex, France
Research Site Recruiting
Rennes, France
Research Site Recruiting
Toulouse Cedex 9, France
Research Site Recruiting
Villejuif Cedex, France
Germany
Research Site Recruiting
Berlin, Germany
Research Site Not yet recruiting
Berlin-Zehlendorf, Germany
Research Site Recruiting
Dresden, Germany
Research Site Recruiting
Esslingen a.N., Germany
Research Site Not yet recruiting
Freiburg, Germany
Research Site Recruiting
Gauting, Germany
Research Site Not yet recruiting
Grosshansdorf, Germany
Research Site Recruiting
Hamburg, Germany
Research Site Recruiting
Hemer, Germany
Research Site Recruiting
Karlsruhe, Germany
Research Site Recruiting
Lubeck, Germany
Research Site Recruiting
Löwenstein, Germany
Research Site Not yet recruiting
Mainz, Germany
Research Site Not yet recruiting
Mannheim, Germany
Hungary
Research Site Recruiting
Matrahaza, Hungary
Research Site Not yet recruiting
Pécs, Hungary
Research Site Not yet recruiting
Székesfehérvár, Hungary
Research Site Not yet recruiting
Tatabanya, Hungary
Research Site Recruiting
Törökbálint, Hungary
Israel
Research Site Recruiting
Beer-Sheva, Israel
Research Site Not yet recruiting
Haifa, Israel
Research Site Recruiting
Jerusalem, Israel
Research Site Not yet recruiting
Kfar Saba, Israel
Italy
Research Site Recruiting
Alessandria, Italy
Research Site Recruiting
Ancona, Italy
Research Site Recruiting
Aviano, Italy
Research Site Not yet recruiting
Bari, Italy
Research Site Recruiting
Bergamo, Italy
Research Site Not yet recruiting
Bologna, Italy
Research Site Recruiting
Candiolo, Italy
Research Site Not yet recruiting
Genova, Italy
Research Site Recruiting
Meldola, Italy
Research Site Not yet recruiting
Milano, Italy
Research Site Recruiting
Milano, Italy
Research Site Recruiting
Orbassano, Italy
Research Site Recruiting
Padova, Italy
Research Site Not yet recruiting
Ragusa, Italy
Research Site Recruiting
Rozzano, Italy
Research Site Recruiting
Siena, Italy
Korea, Republic of
Research Site Not yet recruiting
Jeonnam, Korea, Republic of
Research Site Not yet recruiting
Seoul, Korea, Republic of
Research Site Recruiting
Seoul, Korea, Republic of
Research Site Not yet recruiting
Suwon, Korea, Republic of
Netherlands
Research Site Recruiting
Breda, Netherlands
Research Site Recruiting
Eindhoven, Netherlands
Research Site Recruiting
Rotterdam, Netherlands
Poland
Research Site Recruiting
Gdansk, Poland
Research Site Recruiting
Poznan, Poland
Research Site Recruiting
Szczecin, Poland
Research Site Recruiting
Warszawa, Poland
Romania
Research Site Not yet recruiting
Constanta, Romania
Research Site Recruiting
Craiova, Romania
Russian Federation
Research Site Recruiting
Moscow, Russian Federation
Research Site Recruiting
Nizhny Novgorod, Russian Federation
Research Site Recruiting
Saint-Petersburg, Russian Federation
Research Site Not yet recruiting
Saint-Petersburg, Russian Federation
South Africa
Research Site Recruiting
Kraaifontein, South Africa
Research Site Recruiting
Port Elizabeth, South Africa
Research Site Recruiting
Pretoria, South Africa
Spain
Research Site Recruiting
Barcelona, Spain
Research Site Recruiting
Madrid, Spain
Research Site Not yet recruiting
Mataro, Spain
Research Site Recruiting
Sabadell, Spain
Research Site Recruiting
San Sebastian, Spain
Research Site Recruiting
Sevilla, Spain
Sweden
Research Site Recruiting
Linkoping, Sweden
Research Site Recruiting
Lund, Sweden
Research Site Not yet recruiting
Stockholm, Sweden
Research Site Not yet recruiting
Umea, Sweden
United Kingdom
Research Site Not yet recruiting
Belfast, United Kingdom
Research Site Recruiting
Leeds, United Kingdom
Research Site Recruiting
Leicester, United Kingdom
Research Site Recruiting
London, United Kingdom
Research Site Recruiting
Maidstone, United Kingdom
Research Site Recruiting
Manchester, United Kingdom
Research Site Recruiting
Plymouth, United Kingdom
Research Site Not yet recruiting
Sheffield, United Kingdom
Research Site Recruiting
Southampton, United Kingdom
Research Site Recruiting
Wirral, United Kingdom
Sponsors and Collaborators
MedImmune LLC
  More Information

No publications provided

Responsible Party: MedImmune LLC
ClinicalTrials.gov Identifier: NCT01843374     History of Changes
Other Study ID Numbers: D4880C00003
Study First Received: April 22, 2013
Last Updated: September 19, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by MedImmune LLC:
tremelimumab
pleural, peritoneal
malignant mesothelioma
CTLA-4

Additional relevant MeSH terms:
Lung Neoplasms
Mesothelioma
Neoplasms, Mesothelial
Adenoma
Lung Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Antibodies, Monoclonal
Tremelimumab
Antineoplastic Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014